Biophan CEO Michael Weiner to Participate on Expert Panel for Critical Health Delivery Systems and Nanotechnology Solutions.

ROCHESTER, N.Y. -- CEO Weiner to Outline the Benefits of Nanotechnology on Medical Marketplaces in "The Future of Small Medicine" Event

Biophan Technologies, Inc. (OTCBB: BIPH), a developer of next-generation biomedical technology, has announced that CEO Michael Weiner has been invited to participate on an expert panel designed to explore the impacts of nanotechnology and other technological advances on the future of the healthcare delivery system, to be held today at the Health Technology Center in San Francisco, California.

Biophan's Mr. Weiner will join other technology experts from government, academia, and industry on a select panel entitled, "The Future of Small Medicine: Micro and Nanotechnology in Healthcare." Panel members will discuss the clinical impact of micro and nanotechnologies in orthopedics, neurology, cardiology, oncology, and trauma care. They will also explore the development of technological solutions to enable current and future health delivery systems to combat the nation's healthcare crisis.

"Biophan's role in the biotech community is one of technology-driven innovation and vision," said Mr. Weiner. "Our goal is to improve medical care and the quality of life through our cutting-edge research and development, which leverages our substantial and growing patent and intellectual property portfolio. We are grateful for this unique opportunity to dialog with our colleagues in the healthcare and biotechnology sectors."

About the Health Technology Center

The Health Technology Center's mission (HealthTech) is to create a trusted source of objective, expert and useful information about the future of healthcare technologies. Founded in 2000, HealthTech is a non-profit research and education organization that develops objective technology forecasts, innovative decision-making tools, and facilitates a learning network of experts and health system leaders for the exclusive benefit of its more than 40 Partner organizations: healthcare systems, hospitals, safety-net providers, and government agencies. For more information, visit http://www.healthtech.org.

About Biophan Technologies

Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers and interventional surgical devices such as catheters, guidewires, stents, and other implants to allow them to be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 114 U.S. patents, licenses, or applications. This total includes 36 issued U.S. patents, 6 recently-allowed applications that will issue as patents in the near future, and 72 pending applications at various stages of examination at the U.S. Patent and Trademark Office, plus international applications. The patents cover areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific (NYSE:BSX - News) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects, or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology, the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.